Sol-Gel Technologies (SLGL) Cash & Current Investments (2016 - 2026)
Sol-Gel Technologies' (SLGL) quarterly Cash & Current Investments came in at $10.1 million in Q1 2026, down 40.03% year-on-year from $16.9 million in Q1 2025, and down 57.76% on a QoQ basis from $24.0 million in Q4 2025.
Sol-Gel Technologies (SLGL) Cash & Current Investments (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Cash & Current Investments data on file, last reported at $10.1 million in Q1 2026.
- On a quarterly basis, Cash & Current Investments fell 40.03% year-over-year to $10.1 million in Q1 2026; TTM through Mar 2026 was $10.1 million, a 40.03% decrease from a year earlier, with the FY2025 full-year figure at $24.0 million, up 16.07% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $10.1 million, down from $24.0 million in the prior quarter.
- Over the last five years, Cash & Current Investments for SLGL reached as high as $42.2 million in Q2 2022 and fell as low as $6.7 million in Q3 2025.
- Historically, Cash & Current Investments has averaged $21.4 million across 5 years, with a median of $20.7 million in 2025.
- Across the five-year window, Cash & Current Investments soared 32.46% in 2023 and plunged 49.95% in 2025, its largest moves.
- Year by year, Cash & Current Investments stood at $21.1 million in 2022, then surged by 32.46% to $28.0 million in 2023, then slumped by 30.31% to $19.5 million in 2024, then rose by 23.07% to $24.0 million in 2025, then tumbled by 57.76% to $10.1 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $10.1 million in Q1 2026, $24.0 million in Q4 2025, and $6.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Sol-Gel Technologies | 226.64 Mn | 216.50 Mn | - | 10.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.14 Mn |
| Dec 31, 2025 | 24.00 Mn |
| Sep 30, 2025 | 6.72 Mn |
| Jun 30, 2025 | 20.68 Mn |
| Mar 31, 2025 | 16.90 Mn |
| Dec 31, 2024 | 19.50 Mn |
| Sep 30, 2024 | 13.42 Mn |
| Jun 30, 2024 | 16.72 Mn |
| Mar 31, 2024 | 16.22 Mn |
| Dec 31, 2023 | 27.98 Mn |
| Sep 30, 2023 | 26.14 Mn |
| Jun 30, 2023 | 30.29 Mn |
| Mar 31, 2023 | 15.31 Mn |
| Dec 31, 2022 | 21.13 Mn |
| Sep 30, 2022 | 25.50 Mn |
| Jun 30, 2022 | 42.24 Mn |
| Mar 31, 2022 | 30.25 Mn |
| Dec 31, 2021 | 21.79 Mn |
| Sep 30, 2021 | 43.35 Mn |
| Jun 30, 2021 | 33.20 Mn |